



# YOU'RE INVITED

To register, please:

- CALL 1-855-663-3100 or
  - FAX this page (fill out form below) or
  - VISIT [www.meetingreply.com/HysinglaERprogram](http://www.meetingreply.com/HysinglaERprogram)
- Please use the following unique Invitation Code when registering online:

14924 – 0000

## A New Extended-Release Oral Hydrocodone Bitartrate Therapy

### A Purdue Pharma L.P. Speaker Program

**SPEAKER:** JEFFREY GUDIN, MD  
**MEETING DATE:** 3/26/2015  
**MEETING TIME:** 6:00 PM  
**VENUE:** Hacienda Restaurant  
**VENUE ADDRESS:** 1700 Route 17M  
Goshen, NY 10924

#### To register by fax:

Please fax this page to: **1-212-370-1172** For questions, call: **1-855-663-3100**

☒ **Yes, I will attend.**

Consistent with reporting obligations, including but not limited to the Federal Physician Payment Sunshine Act, Purdue will disclose food and beverage consumed by HCPs as transfers of value. Invitees to Purdue Pharma L.P. Speaker Programs are permitted to attend the educational session and not partake in any food or beverage. Should you wish to attend and not partake in the food or beverage offering, please indicate so upon registration. Attendees are not permitted to order and pay for food and/or beverage that is not provided by Purdue.

NAME \_\_\_\_\_ NPI# \_\_\_\_\_  
ADDRESS \_\_\_\_\_  
CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_  
PHONE \_\_\_\_\_ FAX \_\_\_\_\_  
EMAIL \_\_\_\_\_ SPECIALTY \_\_\_\_\_

PLEASE INDICATE YOUR PROFESSIONAL DESIGNATION BY CHECKING THE APPROPRIATE BOX BELOW

☐ MD ☐ DO ☐ PA ☐ NP ☐ RN\* ☐ RPh\* ☐ PharmD\* ☐ Other \_\_\_\_\_

\*This program is intended for healthcare professionals with prescribing authority only (eg, physicians, nurse practitioners, and physician assistants). In accordance with Purdue Policy and PhRMA guidelines, spouses and guests are not permitted to attend.

#### **WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; AND CYTOCHROME P450 3A4 INTERACTION**

##### Addiction, Abuse, and Misuse

HYSINGLA ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing HYSINGLA ER, and monitor all patients regularly for the development of these behaviors or conditions [see Warnings and Precautions (5.1)].

##### Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of HYSINGLA ER. Monitor for respiratory depression, especially during initiation of HYSINGLA ER or following a dose increase. Instruct patients to swallow HYSINGLA ER tablets whole; crushing, chewing, or dissolving HYSINGLA ER tablets can cause rapid release and absorption of a potentially fatal dose of hydrocodone [see Warnings and Precautions (5.2)].

##### Accidental Ingestion

Accidental ingestion of even one dose of HYSINGLA ER, especially by children, can result in a fatal overdose of hydrocodone [see Warnings and Precautions (5.2)].

##### Neonatal Opioid Withdrawal Syndrome

Prolonged use of HYSINGLA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Warnings and Precautions (5.3)].

##### Cytochrome P450 3A4 Interaction

The concomitant use of HYSINGLA ER with all cytochrome P450 CYP3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Monitor patients receiving HYSINGLA ER and any CYP3A4 inhibitor or inducer [see Warnings and Precautions (5.11), Drug Interactions (7.1), and Clinical Pharmacology (12.3)].

Please read accompanying Full Prescribing Information, including Boxed Warning above.

